Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node

Cancer Immunology, Immunotherapy

Volumn 65, Issue 4, 2016, Pages 405-415

  van den Hout, Mari F C M ^a   Sluijter, Berbel J R ^a   Santegoets, Saskia J A M ^a   van Leeuwen, Paul A M ^a   van den Tol, M Petrousjka ^a   van den Eertwegh, Alfons J M ^a   Scheper, Rik J ^a   de Gruijl, Tanja D ^a  

^a University of Amsterdam   (Netherlands)

Author keywords

CpG; GM CSF; Immunotherapy; Melanoma; Regulatory T cells; Sentinel lymph node

Indexed keywords

AGATOLIMOD; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 10; SARGRAMOSTIM; SODIUM CHLORIDE; TRANSCRIPTION FACTOR FOXP3; ANTINEOPLASTIC AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; OLIGODEOXYRIBONUCLEOTIDE;

ADULT; ARTICLE; CANCER STAGING; CD4 CD8 RATIO; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS PRESENTATION; CUTANEOUS MELANOMA; CYTOKINE PRODUCTION; DENDRITIC CELL; EFFECTOR CELL; FEMALE; FLU LIKE SYNDROME; HUMAN; HUMAN CELL; IMMUNOPOTENTIATION; LYMPH NODE DISSECTION; MALE; MIDDLE AGED; NATURAL KILLER CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE METASTASIS; T LYMPHOCYTE ACTIVATION; TH1 CELL; ADAPTIVE IMMUNITY; AGED; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; IMMUNOLOGY; LYMPH NODE; MELANOMA; PATHOLOGY; SENTINEL LYMPH NODE BIOPSY; SINGLE BLIND PROCEDURE; SKIN NEOPLASMS; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

ADAPTIVE IMMUNITY; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD4-CD8 RATIO; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; KILLER CELLS, NATURAL; LYMPH NODES; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; OLIGODEOXYRIBONUCLEOTIDES; SENTINEL LYMPH NODE BIOPSY; SINGLE-BLIND METHOD; SKIN NEOPLASMS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME;

EID: 84959479995     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1811-z     Document Type: Article

References (43)

1. Thompson JF, Scolyer RA, Kefford RF (2005) Cutaneous melanoma. Lancet 365:687–701
2. Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, Chen JL, Liénard D, Cerottini JC, Cerundolo V (1998) Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 188:1641–1650
3. Munn DH, Mellor AL (2006) The tumor-draining lymph node as an immune-privileged site. Immunol Rev 213:146–158
4. Grotz TE, Mansfield AS, Jakub JW, Markovic SN (2012) Regional lymphatic immunity in melanoma. Melanoma Res 22:9–18
5. Gabrilovich D (2004) Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 4:941–952
6. Cochran AJ, Huang RR, Lee J, Itakura E, Leong SP, Essner R (2006) Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 6:659–670
7. Molenkamp BG, van Leeuwen PAM, van den Eertwegh AJM, Sluijter BJR, Scheper RJ, Meijer S, de Gruijl TD (2006) Immunomodulation of the melanoma sentinel lymph node: a novel adjuvant therapeutic option. Immunobiology 211:651–661
8. Vuylsteke RJCL, van Leeuwen PAM, Meijer S, Wijnands PGJT, Statius Muller MG, Busch DH, Scheper RJ, de Gruijl TD (2002) Sampling tumor-draining lymph nodes for phenotypic and functional analysis of dendritic cells and T cells. Am J Pathol 161:19–26
9. Elliott B, Cook MG, John RJ, Powell BW, Pandha H, Dalgleish AG (2004) Successful live cell harvest from bisected sentinel lymph nodes research report. J Immunol Methods 291:71–78
10. Molenkamp BG, van Leeuwen PAM, Meijer S, Sluijter BJR, Wijnands PGJT, Baars A, van den Eertwegh AJM, Scheper RJ, de Gruijl TD (2007) Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin Cancer Res 13:2961–2969
11. + T-cell reactivity in melanoma patients. Clin Cancer Res 14:4532–4542
12. + T cell reactivity in the sentinel lymph node of GM-CSF-treated stage I melanoma patients is associated with high myeloid dendritic cell content. Clin Cancer Res 12:2826–2833
13. Vuylsteke RJCL, Molenkamp BG, Gietema HA, van Leeuwen PAM, Wijnands PGJT, Vos W, van Diest PJ, Scheper RJ, Meijer S, de Gruijl TD (2004) Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma. Cancer Res 64:8456–8460
14. Lou Y, Liu C, Kim GJ, Liu YJ, Hwu P, Wang G (2007) Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responses. J Immunol 178:1534–1541
15. Sandler AD, Chihara H, Kobayashi G, Zhu X, Miller MA, Scott DL, Krieg AM (2003) CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res 63:394–399
16. Tarhini AA, Leng S, Moschos SJ, Yin Y, Sander C, Lin Y, Gooding WE, Kirkwood JM (2012) Safety and immunogenicity of vaccination with MART-1 (26–35, 27L), gp100 (209–217, 210 M), and tyrosinase (368–376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. J Immunother 35:359–366
17. Sluijter BJ, van den Hout MF, Koster BD, van Leeuwen PA, Schneiders FL, van de Ven R, Molenkamp BG, Vosslamber S, Verweij CL, van den Tol MP, van den Eertwegh AJ, Scheper RJ, de Gruijl TD (2015) Arming the melanoma SLN through local administration of CpG-B and GM-CSF: recruitment and activation of BDCA3/CD141 + DC and enhanced cross-presentation. Cancer Immunol Res 3(5):495–505
18. van der Veen H, Hoekstra OS, Paul MA, Cuesta MA, Meijer S (1994) Gamma probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy. Br J Surg 81:1769–1770
19. Schneiders FL, de Bruin RC, Santegoets SJAM, Bonneville M, Scotet E, Scheper RJ, Verheul HM, de Gruijl TD, van der Vliet HJ (2012) Activated iNKT cells promote Vgamma9Vdelta2-T cell anti-tumor effector functions through the production of TNF-alpha. Clin Immunol 142:194–200
20. Tran DQ, Andersson J, Hardwick D, Bebris L, Illei GG, Shevach EM (2009) Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3 + regulatory T cells allows for their purification from expansion cultures. Blood 113:5125–5133
21. Venken K, Thewissen M, Hellings N, Somers V, Hensen K, Rummens JL, Stinissen P (2007) A CFSE based assay for measuring CD4 + CD25 + regulatory T cell mediated suppression of auto-antigen specific and polyclonal T cell responses. J Immunol Methods 322:1–11
22. + T cells from melanoma sentinel lymph nodes. Clin Immunol 137:221–233
23. Sun J, Tang DN, Fu T, Sharma P (2012) Identification of human regulatory T cells in the setting of T-cell activation and anti-CTLA-4 immunotherapy on the basis of expression of latency-associated peptide. Cancer Discov 2:122–130
24. Willimsky G, Blankenstein T (2005) Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437:141–146
25. Kim PS, Ahmed R (2010) Features of responding T cells in cancer and chronic infection. Curr Opin Immunol 22:223–230
26. Moseman EA, Liang X, Dawson AJ, Panoskaltsis-Mortari A, Krieg AM, Liu YJ, Blazar BR, Chen W (2004) Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4 + CD25 + regulatory T cells. J Immunol 173:4433–4442
27. Kortylewski M, Kujawski M, Herrmann A, Yang C, Wang L, Liu Y, Salcedo R, Yu H (2009) Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy. Cancer Res 69:2497–2505
28. Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR (2008) The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol 181:5396–5404
29. Jung YJ, Seoh JY (2009) Feedback loop of immune regulation by CD4 + CD25 + Treg. Immunobiology 214:291–302
30. Taylor PA, Lees CJ, Blazar BR (2002) The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99:3493–3499
31. Weiner HL (2001) Induction and mechanism of action of transforming growth factor-β-secreting Th3 regulatory cells. Immunol Rev 182:207–214
32. Andersson J, Tran DQ, Pesu M, Davidson TS, Ramsey H, O’Shea JJ, Shevach EM (2008) CD4 + FoxP3 + regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner. J Exp Med 205:1975–1981
33. Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune tolerance. Cell 133:775–787
34. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK (2006) Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212:28–50
35. Levings MK, Sangregorio R, Galbiati F, Squadrone S, de Waal Malefyt R, Roncarolo MG (2001) IFN-α and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol 166:5530–5539
36. Puccetti P, Grohmann U (2007) IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-ĸB activation. Nat Rev Immunol 7:817–823
37. Neeland MR, Elhay MJ, Nathanielsz J, Meeusen EN, de Veer MJ (2014) Incorporation of CpG into a liposomal vaccine formulation increases the maturation of antigen-loaded dendritic cells and monocytes to improve local and systemic immunity. J Immunol 192:3666–3675
38. Moretta L, Ferlazzo G, Bottino C, Vitale M, Pende D, Mingari MC, Moretta A (2006) Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev 214:219–228
39. + T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 167:5247–5253
40. Liu C, Lou Y, Lizee G, Qin H, Liu S, Rabinovich B, Kim GJ, Wang YH, Ye Y, Sikora AG, Overwijk WW, Liu YJ, Wang G, Hwu P (2008) Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest 118:1165–1175
41. Pashenkov M, Goëss G, Wagner C, Hörmann M, Jandl T, Moser A, Britten CM, Smolle J, Koller S, Mauch C, Tantcheva-Poor I, Grabbe S, Loquai C, Esser S, Franckson T, Schneeberger A, Haarmann C, Krieg AM, Stingl G, Wagner SN (2006) Phase II Trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 24:5716–5724
42. Zanoni I, Foti M, Ricciardi-Castagnoli P, Granucci F (2005) TLR-dependent activation stimuli associated with Th1 responses confer NK cell stimulatory capacity to mouse dendritic cells. J Immunol 175:286–292
43. Chapman PB, D’Angelo SP, Wolchok JD (2015) Rapid eradication of a bulky melanoma mass with one dose of immunotherapy. N Engl J Med 372(21):2073–2074